Ani Pharmaceuticals INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
ANI Pharmaceuticals, Inc. convened its 2026 Annual Meeting of Stockholders, highlighting record 2025 financial performance driven by its Rare Disease segment and strong Generics business.
NASDAQ
ANI Pharmaceuticals supplements its proxy statement to clarify information regarding its Amended and Restated 2022 Stock Incentive Plan, specifically detailing non-shareholder approved inducement grants.
NASDAQ
ANI Pharmaceuticals has filed a definitive proxy statement with the SEC.
NASDAQ
ANI Pharmaceuticals announces strong 2024 results with a 26% increase in total revenue and a 17% rise in adjusted non-GAAP EBITDA, driven by its Rare Disease business and strategic acquisitions.
NASDAQ
ANI Pharmaceuticals has filed definitive additional materials related to its proxy statement with the SEC.
NASDAQ
DEF 14A: ANI Pharmaceuticals Reports Strong 2023 Growth, Driven by Rare Disease and Generics Businesses
ANI Pharmaceuticals achieved record financial performance in 2023, with significant revenue and EBITDA growth driven by its Rare Disease and Generics businesses.